Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)1990-472XФедеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации501010.18499/1990-472X-2017-0-67-66-74Original ArticleDINAMIKA POKAZATELEY UROVNYa GORMONOV U MUZhChIN S OZhIRENIEM I VOZRASTNYM ANDROGENODEFITsITOMBindyukovaL M-ZoloedovV I-ChernyshT M-Voronezh State Medical University1512201767667425042020Copyright © 2017, Научно-медицинский вестник Центрального Черноземья2017ожирениеальдостеронвозрастной андрогенодефицит1.Lann D & LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Medical Clinics of North America 2007 91 1063-1077, viii. (doi:10.1016/j.mcna.2007.06.012).2.Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV & Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5α-reductase activity. Diabetes 2008 57 2652-2660. (doi:10.2337/db08-0495).3.Klop B, Elte JW & Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013 5 1218-1240. (doi:10.3390/nu5041218).4.Newell-Price J, Bertagna X, Grossman AB & Nieman LK. Cushing's syndrome. Lancet 2006 367 1605-1617. (doi:10.1016/S0140-6736(06)68699-6).5.Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am | Physiol Endocrinol Med 2007; 293:E1465-78/6.Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008; 51:1252-8.7.Stewart PM. Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome - 11β-hydroxysteroid dehydrogenase type 1.Clinical Medicine 2005 5 142-146. (doi:10.7861/clinmedicine.5-2-142).8.Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metabol 2006; 91:3457-63.9.Stas S, Whaley-Connell A, Habibi), Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148:3773-80.10.Goncharov N, Kolesnikova G, Bydrova S. Quantitative and qualitative parameters of an adrenal steroidogenesis in obese women of reproductive age. Prob Endocrinol 2008; 6:16-21.11.Hannemann A, Meisinger C, Bidlingmaier M, Doring A, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N, Schipf S, LUdemann J, Rettig R, Peters J, Volzke H, Seissler J, Beuschlein F, Nauck M, Reincke M. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011; 164:751-8.12.Briet M, Schiffrin EL. The role of aldosterone in the metabolic syn-drome. Curr Hypertens Rep 2011; 13:163-72.13.Sowers R, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syn-drome and resistant hypertension. Ann Intern Med 2009; 150:776-83.14.Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB 2007; 21: 2185-94.15.Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW& Stewart PM. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocrine Reviews 2013 34 525-555. (doi:10.1210/er.2012-1050).16.Schnackenberg CG, Costell MH, Krosky DJ, Cui J, Wu CW, Hong VS,Harpel MR, Willette RN & Yue TL. Chronic inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. Biomed Research International 2013 427640. (doi:10.1155/2013/427640).17.Traish AM, Kypreos KE. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2010; 214:244-8.18.Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006; 176:1524-7; discussion 1527-8.19.Allan CA, Strauss B), Burger HG, Forbes EA, McLachlan Rl. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med) Aust 2006; 185:424-7.20.Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Current Opin Endocrinol Diabetes Obes 2007; 14:226-34.21.Allan CA, Strauss B), McLachlan Rl. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007;19:448-57.22.Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur | Endocrinol 2006; 155:443-52.23.Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92:3568-72.Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.) Obes 2011; pii:471584.24.Allan CA, Strauss B), McLachlan Rl. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007; 19:448-57.25.Hintikka J, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Lehto SM, Viinamaki H. Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 2009; 6:2049-57.26.Shores MM, Kivlahan DR, Sadak Tl, Li EJ, Matsumoto AM. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009; 70:1009-16.27.Heinemann LA. Aging Males' Symptoms scale: a standardized in-strument for the practice. J Endocrinol Invest 2005; 28:34-8.28.Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad f, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46:80-7.29.Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai do M. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003; 1:77.30.Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011; 165:675-85.31.Caminiti G, Volterrani M, lellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a ,double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54:919-27.32.Malkin CJ, Channer KS, Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2011; 17:262-8.33.Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009; 207:318-27.34.Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, TIMES2 Investigators.35.Hannemann A, MeisingerC, BidlingmaierM, DoringA, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N, Schipf S, LUdemann J, Rettig R, Peters J, Volzke H, Seissler, J, Beuschlein F, NauckM, Reincke M. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011; 164:751-8.36.Briet M, Schiffrin EL. The role of aldosterone in the metabolic syn-drome. Curr Hypertens Rep 2011; 13:163-72.37.Kau MM, Lo MJ, Wang SW, Tsai SC, Chen J), Chiao YC, Yeh JY, Lin H, Shum AY, Fang VS, Ho LT, Wang PS. Inhibition of aldosterone production by testosterone in male rats. Metabolism 1999; 48:1108-14.